Co-sponsored by NERGG and Illumina, Lunch and Learn, Wednesday, November 10, 2021, noon – 1:00 PM ET
An Innovative Payer Partnership for Whole Genome Sequencing in Pediatric Rare Disease
Update your understanding of the current evidence supporting the application of whole-genome sequencing (WGS) and learn of an innovative program to accelerate access and evaluate the impact of insurance coverage.
In recent years, whole exome sequencing (WES) for suspected rare and other genetic disease is becoming standard of care for many clinicians and is reimbursed by many payers (e.g., ~65% of patients have coverage for WES). Whole-genome sequencing (WGS) is a fundamentally similar concept as WES, but with technological and clinical advantages.
Illumina and Harvard Pilgrim Health Care (now “Point32Health”) have partnered on a risk-sharing agreement to open coverage of WGS in pediatric outpatients with suspected genetic diseases. The goal of this project is to evaluate the real-world impact on genetic test utilization and the cost to payers. Results will be published, with an aim to accelerate access to WGS for patients and families.
Presenters: Brock Schroeder PhD of Illumina, Melissa Dempsey MS CGC of Illumina, and Sara Parsons of Point32Health.
To register, click here.